RECENT clinical evidence shows testosterone therapy improves depressive symptoms and specific cognitive domains in hypogonadal men. With the Pentagon newly establishing mandatory screening protocols for low testosterone to evaluate physical and combat readiness, male endocrine health has moved to the forefront of medical practice. As broader testing prompts more patients to seek clinical guidance, physicians face increasing questions regarding whether androgen replacement benefits psychological health and brain function. A systematic review encompassing eleven randomized controlled trials and more than 600 participants evaluated the psychiatric and cognitive outcomes of androgen administration across diverse clinical populations.
The findings demonstrate that testosterone therapy provides measurable antidepressant efficacy, particularly when utilized as an adjunctive treatment. In trials evaluating men with treatment-resistant depression and biochemically confirmed hypogonadism, adding testosterone to existing selective serotonin reuptake inhibitor regimens significantly lowered Hamilton Depression Rating Scale scores compared to placebo. In contrast, trials evaluating testosterone monotherapy for major depressive disorder yielded mixed results, largely due to high placebo response rates. Supraphysiological dosing in young eugonadal men modestly increased aggression without improving mood, suggesting that psychiatric benefits remain confined to testosterone deficient states. Across patient populations, therapy consistently enhanced libido, erectile performance, and overall quality of life.
Cognitive responses to testosterone therapy proved selective rather than broadly restorative. Older hypogonadal men exposed to moderate increases in serum testosterone achieved significant improvements in verbal memory and visuospatial processing. In men with mild Alzheimer disease, therapy produced modest gains on global cognitive scales, including the Mini-Mental State Examination, without halting long-term neurodegenerative progression. Mechanistically, these benefits appear driven by androgen receptors in limbic and prefrontal circuits, alongside increased brain-derived neurotrophic factor expression and enhanced functional connectivity. Across trials, therapy demonstrated an encouraging safety profile with no significant increase in cardiovascular, thromboembolic, or hepatic events. Reported adverse effects remained mild, comprising acne, peripheral edema, and hematocrit elevations that occasionally warranted clinical intervention. Investigators emphasized that testosterone therapy functions best as a supervised complementary approach rather than a primary psychiatric or cognitive remedy.
Reference
Canal de Velasco LM et al. Psychiatric and Cognitive Effects of Testosterone Therapy in Adult Men: A Systematic Review of Clinical Evidence and Mechanistic Insights. Cureus. 2026;18(2):e102894.
Featured Image: Wolfisler on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
